294 related articles for article (PubMed ID: 31466119)
1. Efficacy and safety of topical delgocitinib in patients with chronic hand eczema: data from a randomized, double-blind, vehicle-controlled phase IIa study.
Worm M; Bauer A; Elsner P; Mahler V; Molin S; Nielsen TSS
Br J Dermatol; 2020 May; 182(5):1103-1110. PubMed ID: 31466119
[TBL] [Abstract][Full Text] [Related]
2. The pan-JAK inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16-week randomized phase IIb trial.
Worm M; Thyssen JP; Schliemann S; Bauer A; Shi VY; Ehst B; Tillmann S; Korn S; Resen K; Agner T
Br J Dermatol; 2022 Jul; 187(1):42-51. PubMed ID: 35084738
[TBL] [Abstract][Full Text] [Related]
3. Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study.
Nakagawa H; Nemoto O; Igarashi A; Saeki H; Kaino H; Nagata T
J Am Acad Dermatol; 2020 Apr; 82(4):823-831. PubMed ID: 32029304
[TBL] [Abstract][Full Text] [Related]
4. Delgocitinib ointment in pediatric patients with atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study.
Nakagawa H; Nemoto O; Igarashi A; Saeki H; Kabashima K; Oda M; Nagata T
J Am Acad Dermatol; 2021 Oct; 85(4):854-862. PubMed ID: 34118298
[TBL] [Abstract][Full Text] [Related]
5. Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis.
Nakagawa H; Nemoto O; Igarashi A; Saeki H; Oda M; Kabashima K; Nagata T
J Allergy Clin Immunol; 2019 Dec; 144(6):1575-1583. PubMed ID: 31425780
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis.
Nakagawa H; Nemoto O; Igarashi A; Saeki H; Murata R; Kaino H; Nagata T
J Dermatol; 2020 Feb; 47(2):114-120. PubMed ID: 31820485
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of dupilumab in patients with severe chronic hand eczema with inadequate response or intolerance to alitretinoin: a randomized, double-blind, placebo-controlled phase IIb proof-of-concept study.
Voorberg AN; Kamphuis E; Christoffers WA; Schuttelaar MLA
Br J Dermatol; 2023 Sep; 189(4):400-409. PubMed ID: 37170922
[TBL] [Abstract][Full Text] [Related]
8. Calcipotriol ointment shows comparable efficacy to topical steroids in chronic hand eczema.
Juntongjin P; Pongprasert R
Dermatol Ther; 2019 Jul; 32(4):e12956. PubMed ID: 31070845
[TBL] [Abstract][Full Text] [Related]
9. Treatment with delgocitinib cream improves itch, pain and other signs and symptoms of chronic hand eczema: Results from the Hand Eczema Symptom Diary in a phase IIb randomized clinical trial.
Bauer A; Thyssen JP; Buhl T; Nielsen TSS; Larsen LS; Østerskov AB; Agner T
Contact Dermatitis; 2023 Jul; 89(1):46-53. PubMed ID: 37037780
[TBL] [Abstract][Full Text] [Related]
10. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial.
Bissonnette R; Papp KA; Poulin Y; Gooderham M; Raman M; Mallbris L; Wang C; Purohit V; Mamolo C; Papacharalambous J; Ports WC
Br J Dermatol; 2016 Nov; 175(5):902-911. PubMed ID: 27423107
[TBL] [Abstract][Full Text] [Related]
11. Safety, efficacy, and pharmacokinetics of delgocitinib ointment in infants with atopic dermatitis: A phase 3, open-label, and long-term study.
Nakagawa H; Igarashi A; Saeki H; Kabashima K; Tamaki T; Kaino H; Miwa Y
Allergol Int; 2024 Jan; 73(1):137-142. PubMed ID: 37100717
[TBL] [Abstract][Full Text] [Related]
12. A phase 2a randomized vehicle-controlled multi-center study of the safety and efficacy of delgocitinib in subjects with moderate-to-severe alopecia areata.
Mikhaylov D; Glickman JW; Del Duca E; Nia J; Hashim P; Singer GK; Posligua AL; Florek AG; Ibler E; Hagstrom EL; Estrada Y; Rangel SM; Colavincenzo M; Paller AS; Guttman-Yassky E
Arch Dermatol Res; 2023 Mar; 315(2):181-189. PubMed ID: 35230488
[TBL] [Abstract][Full Text] [Related]
13. Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial.
Papp KA; Bissonnette R; Gooderham M; Feldman SR; Iversen L; Soung J; Draelos Z; Mamolo C; Purohit V; Wang C; Ports WC
BMC Dermatol; 2016 Oct; 16(1):15. PubMed ID: 27716172
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial.
Ruzicka T; Lynde CW; Jemec GB; Diepgen T; Berth-Jones J; Coenraads PJ; Kaszuba A; Bissonnette R; Varjonen E; Holló P; Cambazard F; Lahfa M; Elsner P; Nyberg F; Svensson A; Brown TC; Harsch M; Maares J
Br J Dermatol; 2008 Apr; 158(4):808-17. PubMed ID: 18294310
[TBL] [Abstract][Full Text] [Related]
15. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis.
Ports WC; Khan S; Lan S; Lamba M; Bolduc C; Bissonnette R; Papp K
Br J Dermatol; 2013 Jul; 169(1):137-45. PubMed ID: 23387374
[TBL] [Abstract][Full Text] [Related]
16. The efficacy of a transdermal hydrogel patch containing betamethasone dipropionate for treatment of chronic hand eczema: A single-blind, randomized and controlled trial.
Thaitirarot S; Shuwisitkul D; Udompataikul M; Kamanamool N; Kanokrungsee S
Contact Dermatitis; 2024 Feb; 90(2):153-160. PubMed ID: 37828631
[TBL] [Abstract][Full Text] [Related]
17. A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of alitretinoin (BAL4079) in the treatment of severe chronic hand eczema refractory to potent topical corticosteroid therapy.
Fowler JF; Graff O; Hamedani AG
J Drugs Dermatol; 2014 Oct; 13(10):1198-204. PubMed ID: 25607554
[TBL] [Abstract][Full Text] [Related]
18. Successful retreatment with alitretinoin in patients with relapsed chronic hand eczema.
Bissonnette R; Worm M; Gerlach B; Guenther L; Cambazard F; Ruzicka T; Maares J; Brown TC
Br J Dermatol; 2010 Feb; 162(2):420-6. PubMed ID: 19906075
[TBL] [Abstract][Full Text] [Related]
19. Current and emerging therapies for hand eczema.
Lee GR; Maarouf M; Hendricks AK; Lee DE; Shi VY
Dermatol Ther; 2019 May; 32(3):e12840. PubMed ID: 30693618
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of alitretinoin depending on the concomitant use of topical corticosteroids in chronic hand eczema patients.
Cheon DU; Kim JE; Ko JY; Ro YS
J Dermatol; 2019 Nov; 46(11):998-1005. PubMed ID: 31535403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
